LSTA Valuation

Lisata Therapeutics Inc

Add to Watchlist

Advanced Chart

2.470

+0.07(2.917%)1D

Overview
Forecast
Valuation
Earnings

LSTA Relative Valuation

LSTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LSTA is overvalued; if below, it's undervalued.

Historical Valuation

Lisata Therapeutics Inc (LSTA) is now in the Fair zone, suggesting that its current forward PS ratio of 1255.85 is considered Fairly compared with the five-year average of -1.62. The fair price of Lisata Therapeutics Inc (LSTA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.42

Fair

-1.48

Trailing

Forward

0.01

EV/EBITDA

Lisata Therapeutics Inc. (LSTA) has a current EV/EBITDA of 0.01. The 5-year average EV/EBITDA is 0.78. The thresholds are as follows: Strongly Undervalued below -1.23, Undervalued between -1.23 and -0.23, Fairly Valued between 1.79 and -0.23, Overvalued between 1.79 and 2.80, and Strongly Overvalued above 2.80. The current Forward EV/EBITDA of 0.01 falls within the Historic Trend Line -Fairly Valued range.

0.01

EV/EBIT

Lisata Therapeutics Inc. (LSTA) has a current EV/EBIT of 0.01. The 5-year average EV/EBIT is 0.79. The thresholds are as follows: Strongly Undervalued below -1.05, Undervalued between -1.05 and -0.13, Fairly Valued between 1.71 and -0.13, Overvalued between 1.71 and 2.62, and Strongly Overvalued above 2.62. The current Forward EV/EBIT of 0.01 falls within the Historic Trend Line -Fairly Valued range.

1250.85

Lisata Therapeutics Inc. (LSTA) has a current PS of 1250.85. The 5-year average PS is 33.22. The thresholds are as follows: Strongly Undervalued below -351.76, Undervalued between -351.76 and -159.27, Fairly Valued between 225.71 and -159.27, Overvalued between 225.71 and 418.21, and Strongly Overvalued above 418.21. The current Forward PS of 1250.85 falls within the Strongly Overvalued range.

-1.07

P/OCF

Lisata Therapeutics Inc. (LSTA) has a current P/OCF of -1.07. The 5-year average P/OCF is -0.31. The thresholds are as follows: Strongly Undervalued below -2.54, Undervalued between -2.54 and -1.42, Fairly Valued between 0.81 and -1.42, Overvalued between 0.81 and 1.92, and Strongly Overvalued above 1.92. The current Forward P/OCF of -1.07 falls within the Historic Trend Line -Fairly Valued range.

-1.07

P/FCF

Lisata Therapeutics Inc. (LSTA) has a current P/FCF of -1.07. The 5-year average P/FCF is -0.32. The thresholds are as follows: Strongly Undervalued below -2.91, Undervalued between -2.91 and -1.61, Fairly Valued between 0.98 and -1.61, Overvalued between 0.98 and 2.27, and Strongly Overvalued above 2.27. The current Forward P/FCF of -1.07 falls within the Historic Trend Line -Fairly Valued range.

Lisata Therapeutics Inc (LSTA) has a current Price-to-Book (P/B) ratio of 1.03. Compared to its 3-year average P/B ratio of 0.56 , the current P/B ratio is approximately 84.70% higher. Relative to its 5-year average P/B ratio of 0.62, the current P/B ratio is about 65.87% higher. Lisata Therapeutics Inc (LSTA) has a Forward Free Cash Flow (FCF) yield of approximately -74.77%. Compared to its 3-year average FCF yield of -85.34%, the current FCF yield is approximately -12.39% lower. Relative to its 5-year average FCF yield of -64.80% , the current FCF yield is about 15.39% lower.

0.98

P/B

Median3y

0.56

Median5y

0.62

-75.07

FCF Yield

Median3y

-85.34

Median5y

-64.80

Competitors Valuation Multiple

The average P/S ratio for LSTA's competitors is 228.82, providing a benchmark for relative valuation. Lisata Therapeutics Inc Corp (LSTA) exhibits a P/S ratio of 1250.85, which is 446.65% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LSTA.O

Lisata Therapeutics Inc

Relmada Therapeutics Inc

Moleculin Biotech Inc

Performance Decomposition

Market capitalization of LSTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LSTA in the past 1 year is driven by Unknown.